ALL KEYWORDSPARP InhibitorsRelated SpecialistsShowing 3 of 31Scott RobertsMDKathleen FennMDNeal FischbachMDMore Related SpecialistsRelated Clinical TrialsShowing 2 of 6A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid TumorsPhase 1 CancersPRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP DeficientPhase 1 CancersMore Related Clinical TrialsRelated NewsFamily HealthResearch & Innovation, Doctors & Advice, Family HealthDoctors & AdviceRelated DepartmentsShowing 3 of 40Yale Cancer CenterSurgeryInternal MedicineMore Related Departments
